1
项与 Autologous CD19/CD22 chimeric antigen receptor T-cell therapy(The University of Texas M.D. Anderson Cancer Center) 相关的临床试验Phase I/II Study of Dual CD19-CD22 Chimeric Antigen Receptor (CAR) T Cells in Patients With Advanced CD19+ CD22+ Lymphoid Malignancies
This phase I/II trial studies the side effects and best dose of modified immune cells called CD19-CD22 chimeric antigen receptor (CAR) T cells in treating patients with CD19 positive(+), CD22+ B-acute lymphoblastic leukemia, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma that has come back (recurrent) or does not respond to treatment (refractory). T-cells are collected from the patient and genetic materials called "chimeric antigen receptors (CAR)" are transferred to the collected T-cells. The CAR T-cells are then infused back to the patient's body. Giving CD19- CD22 CAR T cells after chemotherapy may help to control the disease.
100 项与 Autologous CD19/CD22 chimeric antigen receptor T-cell therapy(The University of Texas M.D. Anderson Cancer Center) 相关的临床结果
100 项与 Autologous CD19/CD22 chimeric antigen receptor T-cell therapy(The University of Texas M.D. Anderson Cancer Center) 相关的转化医学
100 项与 Autologous CD19/CD22 chimeric antigen receptor T-cell therapy(The University of Texas M.D. Anderson Cancer Center) 相关的专利(医药)
1
项与 Autologous CD19/CD22 chimeric antigen receptor T-cell therapy(The University of Texas M.D. Anderson Cancer Center) 相关的文献(医药)2020-12-01·Regenerative therapy3区 · 工程技术
Successful treatment of relapsed acute B-cell lymphoblastic leukemia with CD20/CD22 bispecific chimeric antigen receptor T-cell therapy
3区 · 工程技术
ArticleOA
作者: Huang, He ; Hu, Yongxian ; Yu, Jian ; Cui, Jiazhen ; Liang, Zuyu ; Chang, Alex Hongsheng
100 项与 Autologous CD19/CD22 chimeric antigen receptor T-cell therapy(The University of Texas M.D. Anderson Cancer Center) 相关的药物交易